Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver Range Resources: A hidden gem in the mining industry (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Study is paused - not worried in the slightest
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(3)
•••
Comment by riskseekeron Aug 03, 2021 10:58am
257 Views
Post# 33642204

RE:RE:RE:Study is paused - not worried in the slightest

RE:RE:RE:Study is paused - not worried in the slightestAgree about not seeing 4bucks in the fall...maybe above 2...But I disagree that the credibility of the team is shot. Things like this happen and trying to cover them up destroys credibility. Trying to fix them doesn't. 

3 out of 35 over 28 days, is not going to kill this thing off. Probably delay it by a year or more. But if all other indicators (gut health, blood pressure, etc) are good, I think the good data can, in the long term, outweight the bad and will actually accelerate things. (if other issues remaine, the effort to fix the liver problem will be weak). It is good that this came out before P3 as they can more carefully control this game changer.

I'm in for more. With 66Million cash to help resolve this, Antibe isn't worth 1$. Increasing my position and when at 2$ will review it.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities